ClearID blood tests offer a solution where traditional tissue biopsies may fall short. By targeting and analyzing genes that are known to be associated with cancer, ClearID can help inform treatment decisions so doctors can match patients with clinical trials that fit their specific genetic profile.
Currently available tests are listed below. Additional targeted oncogene panels are in development. Cynvenio's unique approach to liquid biopsy includes the analysis of circulating tumor cells, cell-free DNA and germline DNA, allowing for a major differentiation between our tests and tests currently offered in the liquid biopsy space.
Measurement of NK cell activity has been shown to be a useful tool for assessing changes in immuno-surveillance, which could be indicative of a subjective condition or disease where NK cell activity has been shown to be affected.